DKK1 and plasma cell myeloma: LiCl used as a specific inhibitor of GSK3β to increase bone mass post-fracture and to diminish fracture risk Bortezomib, proteasome inhibitor used in treatment of multiple myeloma (MM); also increases bone mass Anti-DKK1 monoclonal antibody (BHQ880) used to inhibit osteolysis in MM or to increase BMD Anti-sclerostin antibody used to increase bone mass